Thyroid Ablation Devices Market - Strategic Insights and Forecasts (2026-2031)

The Global Thyroid Ablation Devices market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6.3%. This growth trajectory is expected to lead the market from USD 0.50 billion in 2026 to a projected USD 0.68 billion by 2031, indicating that the industry is entering a phase of rapid maturity.

Radiofrequency Ablation (RFA) technology currently dominates the market, representing over 70% of clinical applications within the thermal ablation segment, supported by advancements like thyroid-dedicated electrodes from companies such as STARmed Co., Ltd. Additionally, Theraclion's SONOVEIN® robotic platform, utilizing High-Intensity Focused Ultrasound (HIFU), is anticipated to introduce a non-invasive paradigm shift, with marketing authorization planned for Fall 2025.

The Centers for Medicare & Medicaid Services (CMS) implemented official CPT codes for percutaneous radiofrequency ablation as of January 1, 2025. This regulatory milestone provides a standardized framework for insurance coverage, significantly lowering financial barriers for outpatient clinics and propelling the transition from inpatient surgical resection to minimally invasive thermal ablation procedures.

There is an accelerated and structural migration of thyroid procedures from traditional hospital settings to specialized endocrine and interventional radiology centers, including Ambulatory Surgical Centers (ASCs). This shift is primarily driven by the ability to perform thermal ablation under local anesthesia in an outpatient setting, aligning with healthcare cost-containment initiatives and growing patient preference for rapid recovery and minimal post-procedural downtime.

The market is driven by a robust demand for alternatives to traditional thyroidectomy, which carries associated risks like general anesthesia, permanent scarring, and lifelong thyroid hormone replacement. Thermal ablation technologies address these unmet needs by providing precise tissue destruction while preserving healthy thyroid parenchyma and adjacent anatomical structures, supported by updated clinical guidelines and enhanced diagnostic screening.

The report highlights STARmed Co., Ltd. for its thyroid-dedicated electrodes featuring shorter shaft lengths (7–10 cm) optimized for the superficial location of the thyroid gland, which sustains the necessity of RFA. Additionally, Theraclion is noted for its SONOVEIN® robotic platform, a High-Intensity Focused Ultrasound (HIFU) technology, which completed pivotal FDA trials in 2025 and is poised for marketing authorization.